Theravance Biopharma’s $17 Share Sale to Zymeworks Faces Fairness Probe
TBPH•Theravance Biopharma's sale to Zymeworks for $17.00 per share is under scrutiny by Halper Sadeh LLC for potential breaches of fiduciary duty and unfair deal terms. The investigation aims to secure higher consideration, additional disclosures and assess constraints on competing offers.
1. Proposed Zymeworks Acquisition
Theravance Biopharma agreed to be acquired by Zymeworks Inc. for $17.00 per share in cash, representing the total consideration offered to TBPH shareholders.
2. Investigation Initiated by Law Firm
Halper Sadeh LLC has launched an investigation into the proposed transaction, examining potential federal securities law violations and breaches of fiduciary duty related to deal terms that could preclude superior competing offers.
3. Shareholder Rights and Potential Outcomes
The law firm seeks increased deal consideration, further disclosures and other relief for Theravance investors. Shareholders may pursue claims on a contingent fee basis without upfront legal costs.
